SG Americas Securities LLC Has $1.56 Million Stock Position in Trevi Therapeutics, Inc. $TRVI

SG Americas Securities LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 93.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,562 shares of the company’s stock after acquiring an additional 60,017 shares during the quarter. SG Americas Securities LLC owned about 0.10% of Trevi Therapeutics worth $1,560,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Vivo Capital LLC grew its stake in shares of Trevi Therapeutics by 28.7% during the second quarter. Vivo Capital LLC now owns 4,487,903 shares of the company’s stock valued at $24,549,000 after purchasing an additional 1,000,000 shares during the last quarter. Flputnam Investment Management Co. raised its position in Trevi Therapeutics by 1,105.4% in the 3rd quarter. Flputnam Investment Management Co. now owns 1,048,102 shares of the company’s stock worth $9,590,000 after purchasing an additional 961,150 shares during the last quarter. Peregrine Capital Management LLC bought a new position in Trevi Therapeutics in the 3rd quarter worth approximately $5,677,000. Pivotal bioVenture Partners Investment Advisor LLC lifted its holdings in Trevi Therapeutics by 9.7% during the 3rd quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 1,256,782 shares of the company’s stock worth $11,500,000 after buying an additional 110,672 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new position in Trevi Therapeutics during the 3rd quarter worth $820,000. 95.76% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently commented on TRVI. Needham & Company LLC lifted their target price on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. D. Boral Capital reiterated a “buy” rating and issued a $19.00 price target on shares of Trevi Therapeutics in a report on Wednesday, March 18th. JonesTrading lowered their price objective on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Thursday, March 19th. Stifel Nicolaus boosted their price objective on Trevi Therapeutics from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $21.60.

Trevi Therapeutics Price Performance

Shares of TRVI stock opened at $12.81 on Tuesday. The stock has a market cap of $1.64 billion, a PE ratio of -40.03 and a beta of 0.99. The stock has a 50-day moving average of $11.32 and a 200-day moving average of $11.26. Trevi Therapeutics, Inc. has a one year low of $4.85 and a one year high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. As a group, research analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.